Barkly Rare Earths Debuts Strongly on ASX; Multiple Companies Report Progress in December 2025 Quarter
Barkly Rare Earths (ASX: BAK) made a strong debut on the ASX, surging nearly 50% to 29.5c after raising $8 million for its Barkly project, with its IPO priced at 20c and oversubscribed due to rare earth supply chain concerns. Additionally, several companies reported progress, including AuMEGA Metals Ltd's exploration advancements in Canada and Recce Pharmaceuticals Ltd's advancements in its Phase 3 trial in Indonesia. Other notable updates included high-grade PGE3 results from Terra Metals Ltd and positive clinical results from Imugene Ltd's Phase 1b trial.
Theia Market Signal Identification - AI Assisted
Barkly Rare Earths (ASX: BAK) debuted on the ASX, rising nearly 50% to 29.5c after raising $8 million for its Barkly project in the Northern Territory. The IPO, priced at 20c, was oversubscribed amid concerns over rare earth supply chains.
AuMEGA Metals Ltd (ASX:AAM) reported exploration advancements in Newfoundland, Canada, while Recce Pharmaceuticals Ltd advanced its Phase 3 trial for diabetic foot infections in Indonesia. Terra Metals Ltd announced high-grade PGE3 results at its Dante Project.
Provaris Energy Ltd progressed hydrogen shipping and CO₂ storage initiatives. Cobalt Blue Holdings Ltd focused on its Kwinana Cobalt Refinery, and Atomic Eagle Ltd reported a new Exploration Target at its Muntanga Uranium Project in Zambia.
Kairos Minerals Ltd completed its largest drilling program at Mt York Gold Project, and Imugene Ltd achieved positive clinical results in its Phase 1b trial. Prescient Therapeutics Ltd received Orphan Drug Designation for PTX-100 in the EU. Sovereign Metals Ltd recovered heavy rare earth elements from its Kasiya Project in Malawi.
Comments